Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

The GLP-1 receptor agonist revolution comes to nephrology

Nature Reviews Nephrology volume 20, pages 637–638 (2024)Cite this article

Subjects

Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Thomas, M. C., Coughlan, M. T. & Cooper, M. E. The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metab. 35, 253–273 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Ryan, D. H. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat. Med. https://doi.org/10.1038/s41591-024-02996-7 (2024).

  4. Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018).

    Article  CAS  PubMed  Google Scholar 

  6. Tuttle, K. R. et al. Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis. Kidney360 2, 254–262 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. https://doi.org/10.1038/s41591-024-03015-5 (2024).

  9. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2, 801–809 (2014).

    Article  Google Scholar 

  10. Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. https://doi.org/10.1038/s41591-024-03133-0 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia

    Merlin C. Thomas & Mark E. Cooper

Authors
  1. Merlin C. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Cooper.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thomas, M.C., Cooper, M.E. The GLP-1 receptor agonist revolution comes to nephrology. Nat Rev Nephrol 20, 637–638 (2024). https://doi.org/10.1038/s41581-024-00876-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-024-00876-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing